Merck & Co. Inc. (NYSE:MRK) said that, it is pressing ahead with Phase III trials aimed at mimicking the world’s biggest selling drug as it looks to create future growth with biosimilars.
Merck & Co. Inc. (NYSE:MRK) belongs to Healthcare sector. Its net profit margin is 11.20% and weekly performance is 2.16%. On last trading day company shares ended up at $52.10. Merck & Co. Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 2.10%.
Biogen Inc. (NASDAQ:BIIB) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted for Alprolix® (rFIXFc), a recombinant factor IX Fc fusion protein therapy for the treatment of haemophilia B. If approved, Alprolix would be among the first therapies in the European Union (EU) to offer people living with haemophilia B prolonged protection against bleeding episodes with prophylactic dosing intervals.
Biogen Inc. (NASDAQ:BIIB) shares decreased -1.83% in last trading session and ended the day at $268.64. BIIB Gross Margin is 88.50% and its return on assets is 19.60%. Biogen Inc. (NASDAQ:BIIB) quarterly performance is -7.38%.
Ford Motor Company (NYSE:F) said that, On Tuesday, March 22, Bob Shanks, executive vice president and chief financial officer, will host a “Let’s Chat” forum to discuss key items of interest to the investment community.
On 03 March, Ford Motor Company (NYSE:F) shares advanced 2.42% and was closed at $13.54. F EPS growth in last 5 year was 2.10%. Ford Motor Company (NYSE:F) year to date (YTD) performance is -0.66%.
3M Company (NYSE:MMM) ended the last trading day at $159.38. Company weekly volatility is calculated as 1.06% and price to cash ratio as 50.33. 3M Company (NYSE:MMM) showed a weekly performance of 0.25%.
Abraxas Petroleum Corp. (NASDAQ:AXAS)‘s stock had its “buy” rating reissued by Canaccord Genuity in a research note issued to investors on Tuesday, MarketBeat Ratingsreports. They currently have a $2.00 target price on the energy company’s stock. Canaccord Genuity’s price objective points to a potential upside of 119.80% from the company’s current price.
Abraxas Petroleum Corp. (NASDAQ:AXAS) ended the last trading day at $1.03. Company weekly volatility is calculated as 7.26%. Abraxas Petroleum Corp. (NASDAQ:AXAS) showed a weekly performance of 24.10%.